Background: Congenital hepatoblastoma, diagnosed in the first month of life, has been reported to have a poor prognosis; however, a comprehensive evaluation of this entity is lacking.

Procedure: We retrospectively reviewed two patients from the senior authors' personal series and 25 cases identified in the databases of several multicenter group studies (INT-0098, P9645, 881, P9346, HB 89, HB94, and HB 99). We compared this series with cases of congenital hepatoblastoma previously published in the literature.

Results: The 3-year survival in our case series was 86% (18/21) with a follow-up of 44-230 months (median 85.5 months). Presentation and treatment were not substantially different from hepatoblastoma cohorts unselected for age. Survival was comparable to the reported disease free survival for a similar cohort of hepatoblastoma patients unselected for age between 1986 and 2002 (82.5%) [von Schweinitz et al., Eur J Cancer 1997; 33:1243-1249]. The 2-year survival of cases reported in the literature was 0% (0/9) and 42% (10/24) for patients reported before and after 1990, respectively.

Conclusions: Congenital hepatoblastoma does not appear to confer a worse prognosis. The improved survival of our current series of patients, collected from the past 20 years of German and American multicenter trials and personal series, suggests that the outcome of hepatoblastoma at this young age is much better than has been historically reported. More rigorous analysis should be conducted in future multicenter trials. It is possible that congenital hepatoblastoma should be treated like all other patients with hepatoblastoma provided that the child is stable enough to proceed with surgery and chemotherapy.

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.24655DOI Listing

Publication Analysis

Top Keywords

congenital hepatoblastoma
20
hepatoblastoma
9
personal series
8
series cases
8
unselected age
8
multicenter trials
8
congenital
5
reported
5
patients
5
series
5

Similar Publications

Hepatoblastoma in a 13-Month-old Male With Oculofaciocardiodental Syndrome.

J Pediatr Hematol Oncol

January 2025

Division of Haematology/Oncology, Department of Pediatrics, Children's Hospital, London Health Sciences Centre, London, ON, Canada.

Background: Oculofaciocardiodental (OFCD) syndrome is an X-linked dominant condition that is typically lethal in males.

Observations: A 13-month-old male patient with OFCD syndrome presented with hepatoblastoma. He received chemotherapy per standard of care and had a surgical resection with few complications.

View Article and Find Full Text PDF

Background: Specific patients with hepatoblastoma (HB) and hepatocellular carcinoma (HCC) do not meet eligibility criteria for Children's Oncology Group (COG) trials, limiting an understanding of how comorbidities affect the outcome. We define such a population for future-focused care improvements.

Methods: A questionnaire was sent to COG institutional principal investigators to obtain anonymized data regarding patients with a liver tumor diagnosis not enrolled on AHEP1531 due to ineligibility by trial criteria or other reasons (excluding parent/patient preference).

View Article and Find Full Text PDF

A case report of congenital hepatoblastoma.

Int J Surg Case Rep

November 2024

Department of Surgical Oncology, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, People's Republic of China. Electronic address:

Introduction: Reports of congenital hepatoblastoma are rare, and there is limited experience in its management.

Case Presentation: We present a challenging case of congenital hepatoblastoma that was large at the time of presentation, occupying the first and second hepatic portals and deemed inoperable. Although liver tumors was detected in the child during the mother's pregnancy, the initial diagnosis was hepatic hemangioma.

View Article and Find Full Text PDF

Clinical Characteristics and Outcomes of Neonatal Hepatoblastoma: A Single Center Study.

J Pediatr Surg

November 2024

Department of General Surgery, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China. Electronic address:

Article Synopsis
  • Neonatal hepatoblastoma (HB), diagnosed within the first month of life, presents unique challenges in treatment and prognosis, prompting a study to analyze its diagnosis, treatment, and outcomes at a single center.
  • The study observed 79 patients under one year old, identifying 14 with neonatal HB, which exhibited distinct clinical features such as smaller tumor size and higher tumor grades compared to non-neonatal cases, along with significantly elevated AFP levels.
  • Results indicated a 100% three-year survival rate and event-free survival for neonatal HB patients, demonstrating that combined treatment strategies of surgery and chemotherapy can be highly effective, warranting further research in larger populations.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!